Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference

Rhea-AI Summary

Syndax Pharmaceuticals announced management will participate in a fireside chat at B. Riley Securities' 2022 Oncology Conference on January 27, 2022, at 12:00 p.m. ET. The event will be accessible via a live webcast on the Investor section of the Company's website, with a replay available for a limited time. Syndax is focused on developing innovative cancer therapies, including SNDX-5613, axatilimab, and entinostat. For detailed information, visit www.syndax.com.

Positive

• Participation in a notable oncology conference may enhance visibility and interest in the company and its pipeline.
• The presence of management at the conference could indicate confidence in the company's development efforts.

Negative

• None.

WALTHAM, Mass., Jan. 20, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at B. Riley Securities' 2022 Oncology Conference on Thursday, January 27, 2022 at 12:00 p.m. ET.

A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com 
Tel 212.600.1902

Media Contact
Benjamin Kolinski
benjamin.kolinski@gcihealth.com 
Tel 862.368.4464

SNDX-G

View original content:https://www.prnewswire.com/news-releases/syndax-announces-presentation-at-b-riley-securities-2022-oncology-conference-301464483.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

What event will Syndax Pharmaceuticals present at?

Syndax Pharmaceuticals will present at B. Riley Securities' 2022 Oncology Conference on January 27, 2022.

What is the date and time of Syndax's fireside chat?

The fireside chat will be on January 27, 2022, at 12:00 p.m. ET.

How can I access the webcast of Syndax's presentation?

The webcast can be accessed from the Investor section of Syndax's website.

What are some of the therapies in Syndax's pipeline?

Syndax's pipeline includes SNDX-5613, axatilimab, and entinostat.